KALA BIO, Inc. Common Stock
KALAKala Bio, Inc. (KALA) is a biotechnology company focused on developing innovative gene therapies and biologic treatments. The company aims to address unmet medical needs by leveraging cutting-edge genetic engineering technologies to create therapies for rare and serious diseases.
Company News
KALA BIO completed a registered direct offering of 10 million shares at $1.00 per share, raising approximately $10 million. The company plans to use the proceeds to repay debt and for general corporate purposes.
U.S. stocks traded mixed on Monday, with the Dow Jones falling slightly while NASDAQ rose. Carnival reported strong Q3 earnings, while several biotech stocks experienced significant price drops. Oil prices declined, and U.S. pending home sales surged in August.
Clinical-stage biotech Kala Bio reported a Q2 2025 net loss of $1.71 per share, with continued focus on developing KPI-012 for persistent corneal epithelial defects. The company completed patient enrollment in its Phase 2b CHASE trial and expects topline results by September 2025.
The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
